Widely used:Recently Viewed
Clear All
Value Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹6,570 Cr
P/E Ratio
74.41
P/B Ratio
2.78
Industry P/E
37.5
Debt to Equity
0.52
ROE
1.78 %
ROCE
5.49 %
Div. Yield
0 %
Book Value
241.26
EPS
8.72
CFO
₹1,018.39 Cr
EBITDA
₹1,661.00 Cr
Net Profit
₹856.57 Cr
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Shilpa Medicare
| -18.03 | 6.36 | -15.77 | 23.68 | 10.41 | 13.10 | 3.27 |
|
BSE Healthcare
| -7.68 | 6.11 | -2.04 | 19.11 | 18.77 | 22.70 | 8.84 |
|
BSE Small Cap
| -12.49 | 9.35 | -8.34 | 5.55 | 17.55 | 35.38 | 15.06 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Shilpa Medicare
| 154.57 | 18.66 | -47.98 | 19.90 | 59.29 | -28.15 | -37.34 |
|
BSE Small Cap
| 29.04 | 47.52 | -1.80 | 62.77 | 32.11 | -6.85 | -23.41 |
|
BSE Healthcare
| 43.09 | 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | P/E Ratio | ROE |
|---|---|---|---|---|
| 430.45 | 7,004.90 | 25.53 | 12.5 | |
| 5,218.00 | 8,680.23 | 36.69 | 43.77 | |
| 653.00 | 6,015.92 | 22.32 | 12.68 | |
| 745.45 | 6,001.20 | 34.39 | 20.28 |
Five companies that suffered a quality dip
4 min read•By Vishal Goyal
Companies falling short of cash
2 min read•By Rajan Gulati
Shilpa Medicare Limited, together with its subsidiaries, engages in the manufacturing and selling active pharmaceutical ingredients (APIs), finished dosage formulations, biologicals, and other allopathic pharmaceutical preparations in India, the... United States, Europe, and internationally. It's primary oncology APIs include capecitabine, gemcitabine hydrochloride, pemetrexed, axitinib, erlotinib hydrochloride, and irinotecan hydrochloride; and non-oncology APIs, such as ambroxol, tranexmic acid, and ursodeoxycholic acid; as well as novel-drug delivery systems. The company provides contract development and manufacturing services; and formulations, such as tablets, capsules, liquid injections, and lyophilized injectables. In addition, it is involved in manufacture of specialized oncology formulations; and wind power generation activities. Shilpa Medicare Limited was incorporated in 1987 and is based in Raichur, India. Read more
Incorporated
1987
Chairman
Omprakash Inani
Managing Director
Vishnukant Bhutada
Headquarters
Raichur, Karnataka
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View Announcements
The total asset value of Shilpa Medicare Ltd stood at ₹ 3,117 Cr as on 31-Dec-24
The share price of Shilpa Medicare Ltd is ₹668.50 (NSE) and ₹671.80 (BSE) as of 17-Apr-2025 IST. Shilpa Medicare Ltd has given a return of 10.41% in the last 3 years.
Shilpa Medicare Ltd has a market capitalisation of ₹ 6,570 Cr as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Shilpa Medicare Ltd is 2.78 times as on 17-Apr-2025, a 45% discount to its peers’ median range of 5.09 times.
The P/E ratio of Shilpa Medicare Ltd is 74.41 times as on 17-Apr-2025, a 98% premium to its peers’ median range of 37.50 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Shilpa Medicare Ltd and enter the required number of quantities and click on buy to purchase the shares of Shilpa Medicare Ltd.
Shilpa Medicare Limited, together with its subsidiaries, engages in the manufacturing and selling active pharmaceutical ingredients (APIs), finished dosage formulations, biologicals, and other allopathic pharmaceutical preparations in India, the United States, Europe, and internationally. It's primary oncology APIs include capecitabine, gemcitabine hydrochloride, pemetrexed, axitinib, erlotinib hydrochloride, and irinotecan hydrochloride; and non-oncology APIs, such as ambroxol, tranexmic acid, and ursodeoxycholic acid; as well as novel-drug delivery systems. The company provides contract development and manufacturing services; and formulations, such as tablets, capsules, liquid injections, and lyophilized injectables. In addition, it is involved in manufacture of specialized oncology formulations; and wind power generation activities. Shilpa Medicare Limited was incorporated in 1987 and is based in Raichur, India.
The prominent promoters of Shilpa Medicare Ltd. are
| Name of promoters | Holding percentage |
|---|---|
|
VISHNUKANT CHATURBHUJ BHUTADA |
6.51%
|
|
DHARMAVATI BHUTADA |
6.35%
|
|
RAVI KUMAR INNANI |
4.1%
|
|
SURAJ KUMAR INANI |
4.01%
|
|
OM PRAKASH INANI |
2.93%
|
The chairman of the company is Omprakash Inani, and the managing director is Vishnukant Bhutada.
The promoters of Shilpa Medicare Ltd have pledged 3.5% of the total equity as on Mar-25.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
8,577
|
|
|
6,871
|
|
|
5,723
|
|
|
5,669
|
| Shilpa Medicare Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
4.01
|
|
Operating margin(%)
|
16
|
|
Net Margin(%)
|
7.27
|
|
Dividend yield(%)
|
0
|
Yes, TTM profit after tax of Shilpa Medicare Ltd was ₹88 Cr.
₹6.95
(
